soul trial oral semaglutide cardiovascular outcomes 2024 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants soul trial oral semaglutide cardiovascular

Regeneron is also collaborating with AstraZeneca on small-molecule, GPR75-targeting obesity drugs based on their own genetic research

In New England Journal of Medicine (NEJM) Wharton S, et al.N Engl J Med

--- Foundayo may have lower efficacy and more tolerability concerns than injectables, but many patients will strongly prefer an oral option, as we can already see from the 600k prescriptions of Wegovy

Thats a solution that can serve both access and innovation, protect Medicaid budgets and end treatment rationing

Lets explore each type of medication in more detail.

Glucagon-like peptide 1 (GLP1) analogues are licensed options for obesity, but new treatments are required to obtain better weight loss and to directly address other co-morbidities, such as non-alcoholic fatty liver disease